Treatment.com unveils a new medical library to create the future of AI healthcare
VANCOUVER, British Columbia, July 29, 2021 (GLOBE NEWSWIRE) — Treatment.com International Inc. “Treatment or The Company” (CSE: TRUE), a healthcare AI technology company, announces the completion of the world’s most advanced medical database known as the Global Library of Medicine (GLM), creating a new category of tools in healthcare delivery. This medical library is the foundation of Treatment.com’s AI system that can assess patients and will be integrated into products that offer improved patient safety, cost of care, prevention, and overall healthcare outcomes.
Treatment.com has pioneered a new approach to building a medical library which provides individually tailored and intelligently processed knowledge, as opposed to the general data that most medical databases run from. The multi-layered, multi-modular design of this extensive platform provides a medical value exchange to consumers, clinicians, and commercial users.
Built by a growing consortium of more than 50 doctors from 4 continents, the GLM’s architecture includes detailed knowledge of hundreds of complex disease presentations, physical signs, pathology, anatomy, laboratory and x-ray findings, as well as detailed descriptions of where diseases are most likely to occur, how they are transmitted, and who is at the greatest risk.
According to CEO John Fraser, “This unique artificial intelligence platform introduces a new way to access healthcare information and support decisions that we believe will truly change the face of healthcare. The GLM provides up-to-date intelligent processing of information from leading medical textbooks, scientific articles, epidemiology, and clinical experience to meet the increasing demands of modern medical applications. The GLM will be used to empower consumers through the mobile app Cara, provide diagnostic support for clinicians, educators, and commercial users such as payers, ACO’s, clinical research organizations, pharma and the biotech world.”
“The immediate focus of the GLM is to demonstrate the ability of this powerful platform to improve access to individually tailored medical knowledge and support clinical decision making among consumers and medical professionals. The GLM Generation One is a starting point for a next-gen system to enrich, optimize and improve medical practice, medical education and healthcare orchestration, through the use of artificial intelligence.” said Dr. Kevin A. Peterson, MD, MPH, FRCS(Ed), FAAFP Chief Medical Officer of Treatment.com.
Treatment.com will launch its first product, a consumer mobile app Cara this fall.
About Treatment.com
Treatment.com is a disruptive healthcare technology company that is harnessing the power of AI to help Canadians improve their health through personalized recommendations and insights. Based in Vancouver, the company spent the last five years working with a team of world-class doctors, engineers, mathematicians, and AI specialists to develop a complex AI engine that leverages the most robust, personalized data to generate highly predictive and accurate insights. Treatment.com is the parent company of Cara. This fall, Cara will be empowering Canadians to take control of their health with the launch of an innovative mobile app powered by this exclusive AI engine.
For more investor information on Treatment.com please visit https://treatment.com/investors/.
Forward Looking Statement
This news release contains forward-looking statements relating to the future operations of Treatment.com, International, Inc. (Treatment) and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
For more information:
Investor Contact: investors@treatment.com
